

ASSIGNMENT

WHEREAS, we, Hyun-Su BAE of 21-218, Hanshin City Office, 76, Jamiwon-dong, Seocho-gu, Seoul 137-909 Republic of Korea; Moon-Kyu KANG of 301-2202, Buyeong Apt., 2-1, Donong-dong, Namyangju-si, Gyeonggi-do 472-709 Republic of Korea; Jung-Wan OH of 108-1202, Sambu Apt., Sujin-dong, Sujeong-gu, Seongnam-si, Gyeonggi-do 461-180 Republic of Korea; Chong-Woon CHO of 205, Ibam-ri, Duma-myeon, Gyeryong-si, Chungcheongnam-do 321-911 Republic of Korea; Chang-Sook KIM of Na-101, Ihwa-Mansion, 590, Choji-dong, Danwon-gu, Ansan-si, Gyeonggi-do 425-864 Republic of Korea; Hwa-Jin LEE of 385-7, Imun 2(i)-dong, Dongdaemun-gu, Seoul 130-833 Republic of Korea; In-Sop SHIM of 301-1702, Geumho Apt., Yangji-maeul, Sunae-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-920 Republic of Korea; Choon-Gon JANG of 563-1006, Baekseol Jugong Apt., Jeongja-dong, Jangan-gu, Suwon-si, Gyeonggi-do 440-300 Republic of Korea; Hyun CHOI of 123-33, Bugahyeon 1(ii)-dong, Seodaemun-gu, Seoul 120-819 Republic of Korea; Eun-Jung KO of 1-801, Hyundai Royal Apt., Guro 1(ii)-dong, Guro-gu, Seoul 152-051 Republic of Korea; Chang-Jun AN of 833-35, Bangbae 4(sa)-dong, Seocho-gu, Seoul 137-834 Republic of Korea; Hyun-Taek KIM of 3-106, Hyundai Gugi-Villa, Gugi-dong, Jongno-gu, Seoul 110-011 Republic of Korea; Moo-Chang HONG of 1-103, Misung Apt., 414, Apgujeong 1(ii)-dong, Gangnam-gu, Seoul 135-899 Republic of Korea; and Min-Kyu SHIN of 312-99, Hwagyeong-dong, Dongdaemun-gu, Seoul 130-090 Republic of Korea, have invented a certain new and useful invention entitled EXTRACT OF NELUMBINIS SEMEN FOR THE TREATMENT OF DEPRESSION, MEDICINAL COMPOSITE AND HEALTH FOODS INCLUDING THE EXTRACT OF NELUMBINIS SEMEN, for which an application for Letters Patent of the United States has been prepared for filing, said application being identified as Attorney File No. 3529PC-1 and executed on even date herewith;

NOW THEREFORE, be it known that we, the said inventors, for and in consideration of certain good and valuable consideration, the sufficiency and receipt of which is hereby acknowledged, at the request of the assignee do sell, assign and transfer unto said assignee, Purimed Co., Ltd., a Republic of Korea corporation having a place of business at 4th Floor, Minjoktongil Bldg. 325-52, Imun 2(i)-dong, Dongdaemun-gu, Seoul 130-831 Republic of Korea, its successors, legal representatives and assigns, the aforesaid application for the territory of the United States of America and all continuation, divisional, continuation-in-part and reissue applications, all patent applications in foreign countries, all applications pursuant to the Patent Cooperation Treaty, and all applications for extension filed or to be filed for the invention, and all Letters Patent, Invention Registrations, Utility Models, Extensions or Reissues and other patent rights, obtained for the invention in the United States or any other country; we also assign any right, title or interest in and to the invention which has not already been transferred to the assignee; we warrant that we have made no assignment of the invention, application or patent therefor to a party other than Purimed Co., Ltd. and we are under no obligation to make any assignment of the invention, application, or patent therefor to any other party; and we further agree to cooperate with the assignee hereunder in the obtaining and sustaining of any and all such Letters Patent and in confirming assignee's exclusive ownership of the invention, but at the expense of said assignee.

The Commissioner of Patents is hereby authorized and requested to issue the Letters Patent solely in accordance with the terms of this Assignment, to Purimed Co., Ltd., its successors, legal representatives and assigns, as the assignee of the entire right, title and interest therein.

IN WITNESS WHEREOF, the parties hereto have executed this Assignment as of the date indicated hereunder.

Date: Sept. 28, 2006 By: [Signature]
Hyun-Su BAE

Date: Sept. 28, 2006 By: [Signature]
Moon-Kyu KANG

Date: Sept. 28, 2006 By: J. W. OH
Jung-Wan OH

Date: Sept. 28, 2006 By: Cho. C. W
Chong-Woon CHO

Date: Sept. 28, 2006 By: [Signature]
Chang-Sook KIM

Date: Sept. 28, 2006 By: [Signature]
Hwa-Jin LEE

Date: Sept. 28, 2006 By: [Signature]
In-Sop SHIM

Date: Sept. 28, 2006 By: [Signature]
Choon-Gon JANG

Date: Sept. 28, 2006 By: [Signature]
Hyun CHOI

Date: SEPT. 28, 2006 By: E. J. K
Eun-Jung KO

Date: SEPT. 28, 2006 By: [Signature]
Chang-Jun AN

Date: Sept. 28, 2006 By: [Signature]
Hyun-Taek KIM

Date: Sept. 28, 2006 By: [Signature]
Moo-Chang HONG

Date: Sept. 28, 2006 By: [Signature]
Min-Kyu SHIN

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Purimed Co., Ltd.

Application No./Patent No.: 10/599,546 Filed/Issue Date: 09/29/2006

Entitled:

Purimed Co., Ltd., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

<u>/Paul S. Cha/</u>	<u>2008-09-23</u>
Signature	Date
<u>Paul S. Cha</u>	<u>303.866.0631</u>
Printed or Typed Name	Telephone Number
<u>Patent Attorney</u>	
Title	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.